Early clinical experience with imipenem-cilistatin.
We treated 15 patients with 16 proven bacterial infections with imipenem-cilistatin. Nine isolates were gram positive cocci, the remaining ten being gram negative bacilli and all had MICs less than or equal to 2.0 mg/l. Eight patients had respiratory tract infections, four urinary tract infections and there were three others. Twelve of 16 infections were microbiologically cured. There were no important drug side effects or toxicity. Imipenem-cilistatin is a potentially useful formulation.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D015377:Cilastatin; D003521:Cyclopropanes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D015378:Imipenem; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D012141:Respiratory Tract Infections / Q000188:drug therapy; D013845:Thienamycins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014552:Urinary Tract Infections / Q000188:drug therapy
D003521:Cyclopropanes; D013845:Thienamycins; D015377:Cilastatin; D015378:Imipenem